阿那曲唑治疗绝经后晚期乳腺癌的临床疗效分析被引量：9

Analysis of Clinical Effects of Anastrozole for Post-menopausal Advanced Breast Cancer Patients

导出

摘要目的探讨阿那曲唑治疗绝经后晚期乳腺癌的临床疗效。方法回顾性分析阿那曲唑一线治疗301例绝经后晚期乳腺癌全国多中心的临床资料及疗效。结果 301例均可评价疗效,中位显效时间为2～3个月。CR为11.6%(35/301),PR为38.2%(115/301)。总客观缓解率(ORR)为49.8%(150/301)。中位疾病进展时间(TTP)为12个月。≥70岁者TTP为12个月,ORR为64.2%,均优于<70岁者。非内脏转移组(TTP为12个月,ORR为61.9%)优于肝脏以外内脏转移组(TTP为6个月,ORR为37.9%);肝脏以外内脏转移组TTP和ORR优于肝脏转移组(TTP3个月,ORR为7.1%)。激素受体双阳性组TTP为12个月和ORR为57.8%,明显优于激素受体单阳性组[ER(+)PR(-)、ER(-)PR(+)组];ER(+)PR(-)组TTP、ORR与ER(-)PR(+)组比较无显著性差异。结论阿那曲唑作为绝经后晚期乳腺癌患者内分泌一线治疗选择,能够有效提高疾病客观缓解率和延长疾病进展时间。 Objective To study the effects of anastrozole in postmenopausal patients with advanced breast cancer.Methods Retrospective analysis of clinical data and effects on 301 postmenopausal advanced breast cancer patients first-line treated with Anastrozole.Results Effects on all cases could be evaluated.Median effectual time is 2~3 months.CR is 11.6%（35/301）,PR is 38.2%（115/301）.ORR is 49.8%（150/301）,TTP is 12 months.The group of patients older than 70-year-old：TTP is 12 months and ORR is 64.2%,which was superior to that of patients younger than 70-year-old.Also,effects for non-organs metastasis group is better than that of organ metastasis except of liver metastasis;and TTP and ORR of non-liver organ metastasis group is superior to that of liver metastasis group.TTP of ER＋/PR＋ group is 12 months,and ORR is 57.8%,which is significantly better than that of ER＋/PR-group and ER-/PR＋ group;and no significant difference of TPP or ORR between ER＋/PR-and ER-/PR＋ group.Conclusion As the first-line treatment options in post-menopausal advanced breast cancer patients,Anastrozole could improve ORR and prolong TTP effectively.

作者张敏李春艳郝晓甍张瑾

机构地区天津医科大学附属肿瘤医院

出处《实用癌症杂志》 2010年第3期270-273,共4页 The Practical Journal of Cancer

关键词阿那曲唑芳香化酶抑制剂内分泌治疗乳腺癌 Anastrozole Aromatase inhibitor Endocrine therapy Breast Cancer

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

1Buzdar AU.New generation aromatase inhitors-form the advanced to the adjuvant setting[J].Breast Cancer Res Treat,2002,75(Suppl 1):S13.
2Chung CT,Carlson RW.The role of aromatase inhibitors in early breast cancer[J].Curr Treat Options Oncol,2003,4(2):133.
3Aman Buzdar on behalf of the ATAC trialist's group.MD Anderson Cancer Centre,Houson,TX,USA.The ATAC trial in postmenopausal women with early breast cancer-updated effi-cacy results based on a median follow up of 47 months[J].Lancet,2002,359:2131.
4Dixson J M,Love CDB,Tucker S,et al.Letrozole as primary medical therapy for locally advanced and large operable breast cancer[J].Proc ASCO,1998,17:104.
5Bajetta E,Zilembo N,Guillevin L,et al.Endocrine trial comparing 0.5 and 2.5 mg of letrozole in postmenopausal patients with advanced breast cancer[J].Proc ASCO,1998,17:229.
6Bertelli G,Garrone O,Merlano M,et al.Sequential use of aromatse inactivators and inhitors and inhibitor in advanced breast cancer[J].Proc Am Soc Clin Oncol,2002,21:60a.
7Baum M,Budzar AU,Cuzick J,et al.Anastrozole alone or in combitination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomized trial[J].Lancet,2002,359(9324):2132.
8徐崇锐.绝经期后乳腺癌术后:阿那曲唑优于他莫昔芬[J].循证医学,2004,4(2):66-66. 被引量：2